Press Releases

All Releases
Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine
Jun 2, 2015
PDF 16.8 KB
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global Healthcare Conference in New York City
May 28, 2015
PDF 8.8 KB
Nektar Therapeutics Reports Financial Results for the First Quarter of 2015
Apr 30, 2015
PDF 25.8 KB
Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets
Apr 23, 2015
PDF 10.0 KB
Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
Apr 16, 2015
PDF 14.6 KB
Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference
Apr 13, 2015
PDF 8.4 KB
Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca
Apr 2, 2015
PDF 12.0 KB
MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US
Mar 31, 2015
PDF 14.3 KB
AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US
Mar 19, 2015
PDF 12.4 KB
Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control in Patients with Advanced Breast Cancer in Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08)
Mar 17, 2015
PDF 22.2 KB
Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain
Feb 25, 2015
PDF 18.4 KB
Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results
Feb 24, 2015
PDF 26.2 KB
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets
Feb 17, 2015
PDF 10.7 KB
Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
Feb 11, 2015
PDF 61.9 KB
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Jan 6, 2015
PDF 8.9 KB
Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
Dec 11, 2014
PDF 17.5 KB
MOVENTIG® Approved In The European Union For Opioid-Induced Constipation
Dec 9, 2014
PDF 10.3 KB
Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
Dec 1, 2014
PDF 60.3 KB
Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model
Nov 20, 2014
PDF 13.7 KB
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014
Nov 6, 2014
PDF 28.2 KB
Showing 1-20 of 220 Page: 1 2 3 ... 11  Next 20
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide